Fewer than 10% of patients that would benefit from GLP-1 drugs including Wegovy are able to get them, warns the global health agency as it releases its inaugural advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just access to this class of drugs.
Per forecasts, over two billion are projected to be obese by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major obstacles to widespread availability to the treatments that can assist patients in reducing considerable weight, says the body.
GLP-1 Therapy Shortage
Even under the present best projected case, the production of these medications could only cover about 100 million people – under 10% of those who need them, per the health organization.
The guideline calls on nations and manufacturers to widen access, by approaches including licensing agreements.
A patent on a key compound – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Jabs Function
These medications imitate a body's own hormone to reduce digestion speed, curb appetite and boost feelings of fullness so individuals reduce food intake.
Individuals typically see weight reduction within a few weeks of commencing the regular doses.
Studies suggests patients may regain a significant portion after a year of discontinuing the medication, because their normal hunger return.
To be overweight or obese increases your likelihood for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns people in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.
